Jazz Pharmaceuticals JAZZ Free cash flow yield
Free cash flow yield at other companies
Other financials
Where this comes from
Calculated from Jazz Pharmaceuticals’s reported figures.
Based on trailing twelve months.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's free cash flow yield.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's free cash flow yield?
- Jazz Pharmaceuticals (JAZZ) reported free cash flow yield of 10.9% in Q1 2026.
- How has Jazz Pharmaceuticals's free cash flow yield changed year-over-year?
- Jazz Pharmaceuticals's free cash flow yield decreased by 45.6% year-over-year, from 20.1% to 10.9%.
- What is the long-term trend for Jazz Pharmaceuticals's free cash flow yield?
- Over 5 years (2020 to 2025), Jazz Pharmaceuticals's free cash flow yield has grown at a 7.6% compound annual growth rate (CAGR), from 8.7% to 12.6%.
- What does free cash flow yield mean?
- The spendable cash the business throws off each year as a percentage of its market price.
- How do you interpret free cash flow yield?
- Higher yield can mean better value — you pay less for each dollar of cash generated. A useful sanity check against earnings-based multiples, which non-cash items can distort.
- How does free cash flow yield compare across companies?
- Comparable across cash-generative companies; less meaningful for firms in heavy-investment phases with temporarily negative FCF.